| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2000 ( Subtotal = $0 ) |
| | 2000 | 1999 | UNKNOWN FDA RECIPIENT | FDA (98) | | | | | USA | FDR001044 | EFFICACY OF PERTUSSIS IMMUNE GLOBULIN INTRAVENOUS | 03 | 03 | FDA | 9/27/2000 | $0 |
|
| Issue Date FY: 1999 ( Subtotal = $67,186 ) |
| | 1999 | 1999 | UNKNOWN FDA RECIPIENT | FDA (98) | | | | | USA | FD-R-001044 | "EFFICACY OF PERTUSSIS IMMUNE GLOBULIN, INTRAVENOUS" | 2 | 03 | FDA | 9/28/1999 | $48,436 |
| | 1999 | 1999 | UNKNOWN FDA RECIPIENT | FDA (98) | | | | | USA | FD-R-000843 | METHOTREXATE-AZONE GEL IN MYCOSIS FUNGOIDES | 7 | 02 | FDA | 9/28/1999 | $18,750 |
| | 1999 | 1998 | UNKNOWN FDA RECIPIENT | FDA (98) | | | | | USA | FD-R-001044 | "EFFICACY OF PERTUSSIS IMMUNE GLOBULIN, INTRAVENOUS" | 1 | 03 | FDA | 8/9/1999 | $0 |
|
| Issue Date FY: 1998 ( Subtotal = $271,854 ) |
| | 1998 | 1998 | UNKNOWN FDA RECIPIENT | FDA (98) | | | | | USA | FD-R-001044 | "EFFICACY OF PERTUSSIS IMMUNE GLOBULIN, INTRAVENOUS" | 00 | 03 | FDA | 9/30/1998 | $199,324 |
| | 1998 | 1998 | UNKNOWN FDA RECIPIENT | FDA (98) | | | | | USA | FD-U-001576 | FACTORS AFFECTING NUMBERS OF ACID-RESISTANT ESCHERICHIA COLI IN CATTLE | 00 | 01 | FDA | 9/29/1998 | $72,530 |
| | 1998 | 1997 | UNKNOWN FDA RECIPIENT | FDA (98) | | | | | USA | FD-U-001415 | RESOURCES FOR PHARMACOEPIDEMIOLOGY IN SASKATCHEWAN | 02 | 01 | FDA | 9/25/1998 | $0 |
| | 1998 | 1997 | UNKNOWN FDA RECIPIENT | FDA (98) | | | | | USA | FD-U-001415 | RESOURCES FOR PHARMACOEPIDEMIOLOGY IN SASKATCHEWAN | 01 | 01 | FDA | 4/7/1998 | $0 |
| | 1998 | 1996 | UNKNOWN FDA RECIPIENT | FDA (98) | | | | | USA | FD-U-000976 | SASKATCHEWAN HEALTH - ADVERSE EFFECTS OF MARKETED DRUGS | 4 | 03 | FDA | 8/3/1998 | $0 |
| | 1998 | 1996 | UNKNOWN FDA RECIPIENT | FDA (98) | | | | | USA | FD-U-000976 | SASKATCHEWAN HEALTH - ADVERSE EFFECTS OF MARKETED DRUGS | 04 | 03 | FDA | 9/25/1998 | $0 |
|
|
